Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Nivolumab Market Forecast: Value Set To Climb From $2.16 Billion To $3.62 Billion
The nivolumab market has experienced substantial expansion in recent years. Its value is projected to increase from $1.92 billion in 2025 to $2.17 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.9%. The historical growth of this market is primarily due to factors such as the rising incidence of melanoma and NSCLC, the early approvals of nivolumab for metastatic cancers, the expansion of hospital infrastructure for oncology treatment, increased activity in oncology research and clinical trials, and the growing adoption of monoclonal antibody therapies.
The nivolumab market size is anticipated to experience substantial growth in the coming years, projected to reach $3.63 billion by 2030 with a compound annual growth rate (CAGR) of 13.8%. This expansion during the forecast period can be attributed to several factors including the broadening of nivolumab indications, the increasing geriatric cancer population, its integration into combination therapies, escalating investment in biologics manufacturing, and the development of oncology infrastructure in emerging markets. Key trends influencing this period encompass advancements in immuno-oncology, the evolution of combination therapies, personalized cancer treatment approaches, the expansion of hospital-based oncology services, and the rising adoption of targeted therapies.
Get A Free Sample Report With In-Depth Market Insights:
Nivolumab Market Growth Factors: What’s Supporting Expansion?
The growing embrace of personalized medicine is anticipated to propel the expansion of the Nivolumab market in the future. This medical strategy customizes treatment and prevention plans according to an individual’s distinct genetic composition, way of life, and surroundings, moving away from standardized approaches. Its prevalence is on the rise, thanks to developments in genetic testing, which enable therapies to be precisely matched to each patient’s specific profile. Nivolumab functions as a personalized medicine, precisely targeting particular immune pathways determined by a patient’s tumor characteristics, thereby providing more customized and potent cancer therapy. For example, the Personalized Medicine Coalition, a US-based non-profit organization, announced in February 2024 that the FDA had sanctioned 16 novel personalized therapies for rare disease patients in 2023, marking a considerable jump from the six approvals in 2022. Consequently, the expanding use of personalized medicine is fueling the growth of the Nivolumab market.
Nivolumab Market Segment Outlook: Which Categories Are Growing Fastest?
The nivolumab market covered in this report is segmented –
1) By Type: Injection 4mL, Injection 10mL
2) By Route Of Administration: Intravenous, Other Routes Of Administration
3) By Application: Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma Of The Head And Neck (SCCHN), Renal Cell Carcinoma (RCC), Other Applications
4) By End-User: Clinic, Hospital, Other End-Users
Nivolumab Market Industry Trends: What’s Reshaping Demand?
Major companies in the nivolumab market are prioritizing the development of new formulations and the expansion of treatment indications to improve patient convenience and bolster their immuno-oncology portfolios. For example, in December 2024, the Food and Drug Administration, a US-based federal agency, granted approval for Opdivo Qvantig, a subcutaneous formulation of nivolumab combined with hyaluronidase-nvhy, for use across all previously approved adult solid-tumor indications for intravenous nivolumab. This novel option allows for monotherapy, maintenance therapy after Opdivo plus Yervoy, or combination treatment with chemotherapy or cabozantinib. The approval is substantiated by the Phase 3 CHECKMATE-67T trial, which demonstrated comparable drug exposure, a similar safety profile, and a slightly higher response rate than IV nivolumab in patients with advanced renal cell carcinoma. With its flexible dosing schedules and sustained efficacy, the subcutaneous version provides a more convenient alternative for patients and reinforces Bristol Myers Squibb’s immuno-oncology portfolio.
Nivolumab Market Leading Companies And Competitive Benchmarking
Major companies operating in the nivolumab market are Bristol-Myers Squibb Company, Ono Pharmaceutical Co. Ltd., Xbrane Biopharma AB, NeuClone Therapeutics Inc., Dr. Reddy’s Laboratories Ltd., Biocon Limited, Samsung Bioepis Co. Ltd., Celltrion Inc., Amneal Pharmaceuticals LLC, Lupin Ltd., Intas Pharmaceuticals Ltd., Hetero Biopharma Ltd., Reliance Life Sciences Pvt. Ltd., Zydus Lifesciences Limited, mAbxience, Shanghai Henlius Biotech Inc., Innovent Biologics Inc., WuXi Biologics, Lonza Group AG, Samsung Biologics
View The Full Nivolumab Market Report:
Nivolumab Market Regional Analysis And Leading Geography
North America was the largest region in the nivolumab market in 2025. The regions covered in the nivolumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
